CN114025785A - 慢性炎症和病毒感染的诊断和治疗 - Google Patents

慢性炎症和病毒感染的诊断和治疗 Download PDF

Info

Publication number
CN114025785A
CN114025785A CN202080026317.6A CN202080026317A CN114025785A CN 114025785 A CN114025785 A CN 114025785A CN 202080026317 A CN202080026317 A CN 202080026317A CN 114025785 A CN114025785 A CN 114025785A
Authority
CN
China
Prior art keywords
nmi
ifp35
antibody
seq
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080026317.6A
Other languages
English (en)
Inventor
梁欢欢
刘迎芳
于杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Enmai Biotechnology Co ltd
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010122554.4A external-priority patent/CN113311164A/zh
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Publication of CN114025785A publication Critical patent/CN114025785A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)

Abstract

本申请提供一种慢性炎症的诊断和治疗方法。本申请提供的一种技术方案是试剂在制备预防和/或治疗慢性炎症疾病的产品中的应用：所述试剂为抑制被分泌到细胞外作为炎症因子的异常含量的IFP35和/或NMI的活性的物质。实验证明用抗体等抑制被分泌到细胞外作为炎症因子的异常含量的IFP35和/或NMI的活性，可以有效治疗慢性炎症疾病。本申请还以IFP35和/或NMI作为靶点，为病毒感染、特别是新型冠状病毒(COVID‑19)感染，提供了诊断/辅助诊断和治疗的方法和工具。

Description

PCT国内申请，说明书已公开。

Claims (49)

  1. PCT国内申请，权利要求书已公开。
CN202080026317.6A 2019-04-01 2020-03-31 慢性炎症和病毒感染的诊断和治疗 Pending CN114025785A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019102562203 2019-04-01
CN201910256220 2019-04-01
CN2020101225544 2020-02-27
CN202010122554.4A CN113311164A (zh) 2020-02-27 2020-02-27 新型冠状病毒（covid-19）及其他病毒感染的诊断和治疗
PCT/CN2020/082296 WO2020200186A1 (zh) 2019-04-01 2020-03-31 慢性炎症和病毒感染的诊断和治疗

Publications (1)

Publication Number Publication Date
CN114025785A true CN114025785A (zh) 2022-02-08

Family

ID=72664628

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080026317.6A Pending CN114025785A (zh) 2019-04-01 2020-03-31 慢性炎症和病毒感染的诊断和治疗

Country Status (5)

Country Link
US (1) US20240043511A1 (zh)
EP (1) EP3949978A4 (zh)
JP (1) JP7475366B2 (zh)
CN (1) CN114025785A (zh)
WO (1) WO2020200186A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432285A (zh) * 2022-03-06 2022-05-06 江苏省人民医院（南京医科大学第一附属医院） Resatorvid上调EFTUD2表达和抑制HBV药物中的用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427552B (zh) 2014-08-22 2022-12-20 广州英恩迈生物医药科技有限公司 防治与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
CN113234153B (zh) * 2021-04-07 2022-12-20 中山大学 一批识别ifp35家族蛋白的单克隆抗体及其在免疫识别等方面的应用
CN116064763A (zh) * 2021-07-09 2023-05-05 广州恩迈生物科技有限公司 以ifp35和nmi为靶点的疾病诊断和治疗
WO2023008503A1 (ja) * 2021-07-28 2023-02-02 慶應義塾 重症化予測装置、重症化予測方法、及びプログラム

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028460A2 (en) * 1997-12-03 1999-06-10 Leadd B.V. Molecules interacting with apoptin
CN101365802A (zh) * 2005-10-28 2009-02-11 生物梅里埃股份公司 癌症检测方法
CN107427552A (zh) * 2014-08-22 2017-12-01 中国科学院生物物理研究所 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
CN108169490A (zh) * 2017-11-06 2018-06-15 中国人民解放军第二军医大学第二附属医院 一组用于评估胶质母细胞瘤预后的联合蛋白及其应用
US20180258484A1 (en) * 2012-05-28 2018-09-13 The Royal Institution For The Advancement Of Learning/Mcgill University Inflammation-enabling polypeptides and uses thereof
WO2019025624A1 (en) * 2017-08-03 2019-02-07 Ose Immunotherapeutics BIOMARKERS FOR ASSESSING STATUS OF RESPONSE TO TREATMENT OF INFLAMMATORY CONDITION OR DISEASE AFFECTING THE DIGESTIVE TUBE AS AN INFLAMMATORY BOWEL DISEASE IN HUMAN PATIENTS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028460A2 (en) * 1997-12-03 1999-06-10 Leadd B.V. Molecules interacting with apoptin
CN101365802A (zh) * 2005-10-28 2009-02-11 生物梅里埃股份公司 癌症检测方法
US20180258484A1 (en) * 2012-05-28 2018-09-13 The Royal Institution For The Advancement Of Learning/Mcgill University Inflammation-enabling polypeptides and uses thereof
CN107427552A (zh) * 2014-08-22 2017-12-01 中国科学院生物物理研究所 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
WO2019025624A1 (en) * 2017-08-03 2019-02-07 Ose Immunotherapeutics BIOMARKERS FOR ASSESSING STATUS OF RESPONSE TO TREATMENT OF INFLAMMATORY CONDITION OR DISEASE AFFECTING THE DIGESTIVE TUBE AS AN INFLAMMATORY BOWEL DISEASE IN HUMAN PATIENTS
CN108169490A (zh) * 2017-11-06 2018-06-15 中国人民解放军第二军医大学第二附属医院 一组用于评估胶质母细胞瘤预后的联合蛋白及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
""多发性硬化症的研究进展"", 世界临床医学, vol. 11, no. 7, pages 118 - 120 *
MARTIN S. WEBER ET AL.: ""The role of antibodies in multiple sclerosis"", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1812, pages 239 - 245 *
ZHIKAI XIAHOU ET AL.: ""NMI and IFP35 serve as proinflammatory DAMPs during cellular infection and injury"", NATURE COMMUNICATIONS, vol. 8, pages 1 - 11 *
叶倩宸等: ""干扰素诱导蛋白Nmi与人巨细胞病毒皮层蛋白UL23相互作用区域的研究"", 中国病理生理杂志, no. 07, pages 126 - 132 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432285A (zh) * 2022-03-06 2022-05-06 江苏省人民医院（南京医科大学第一附属医院） Resatorvid上调EFTUD2表达和抑制HBV药物中的用途

Also Published As

Publication number Publication date
JP7475366B2 (ja) 2024-04-26
WO2020200186A1 (zh) 2020-10-08
US20240043511A1 (en) 2024-02-08
JP2022531838A (ja) 2022-07-12
EP3949978A1 (en) 2022-02-09
EP3949978A4 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
WO2020200186A1 (zh) 慢性炎症和病毒感染的诊断和治疗
US7736648B2 (en) Anti-RSV G protein antibodies
UA126381C2 (uk) Нові антитіла, які специфічно зв'язуються з епітопами вірусу зіка, та їх застосування
EP4019541A1 (en) Humanized monoclonal antibody for 2019 novel coronavirus and use thereof
Baral et al. Treatment and prevention strategies for the COVID 19 pandemic: a review of immunotherapeutic approaches for neutralizing SARS-CoV-2
US11905330B1 (en) Methods for weight reduction
US20120020980A1 (en) High affinity human antibodies to human cytomegalovirus (cmv) gb protein
TW202210506A (zh) 用抗ＳＡＲＳ—ＣｏＶ—２刺突醣蛋白抗體治療或預防ＳＡＲＳ—ＣｏＶ—２感染及ＣＯＶＩＤ—１９之方法
EP2376119B1 (en) Anti-hcv monoclonal antibody as a medicament for the therapeutic treatment and prevention of hcv infections
Zhu et al. In vitro neutralization of nervous necrosis virus by a nanobody binding to the protrusion domain of capsid protein
BR112016027671B1 (pt) Uso de um anticorpo
CN113667011B (zh) 制备抗原结合单元的方法
CN113144194B (zh) 一种GP73抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用
CN114773461B (zh) 乙型脑炎病毒抗体1d11及其应用
WO2022138911A1 (ja) ヒト抗ＳＡＲＳ－ＣｏＶ２ウイルス抗体
WO2012030778A1 (en) Canine kobuvirus sequences and uses thereof
WO2014097762A1 (ja) 高病原性トリインフルエンザに対する抗体
TWI688653B (zh) 人源抗腸病毒７１型單株抗體的製法、產物及其應用
Guo et al. Construction of immune human library and screening of neutralizing antibodies specific to glycoprotein of severe fever with thrombocytopenia syndrome virus
KR20230018463A (ko) 정신 질환의 치료에 사용하기 위한 항-herv-w 엔벨로프 단백질 항체
Adair et al. Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection
CN113311164A (zh) 新型冠状病毒（covid-19）及其他病毒感染的诊断和治疗
KR20230139754A (ko) 코로나 19 바이러스 감염 예방 및 감염증 치료용 조성물
CN117069828A (zh) 一种抗带状疱疹病毒gE蛋白单克隆抗体的制备及其应用
CN115028714A (zh) 一种检测冠状病毒的抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230524

Address after: Room 207, Building B, Creator Park, No. 2 Ruitai Road, Huangpu District, Guangzhou City, Guangdong Province, 510000

Applicant after: Guangzhou Enmai Biotechnology Co.,Ltd.

Address before: 510275 No. 135 West Xingang Road, Guangdong, Guangzhou

Applicant before: SUN YAT-SEN University

TA01 Transfer of patent application right